Zilretta® (triamcinolone acetonide extended-release injectable suspension)

Covered only for intra‑articular management of knee osteoarthritis as a single 32 mg injection (no re‑treatment of a previously Zilretta‑treated knee and no coverage for other joints). Approval requires radiologic confirmation of knee OA, documentation of inadequate response to a prior intra‑articular corticosteroid, confirmation the knee has not previously received Zilretta, and records showing the single 32 mg intra‑articular knee injection.

"Zilretta is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee."

Sign up to see full coverage criteria, indications, and limitations.